Phosphate Therapeutics, a UK-based independent specialty pharmaceutical company focused on the development of mineral-derived hospital pharmaceuticals, has raised up to €10.5m in funding from Inventages Venture Capital.
The company intends to use the capital to complete the Phase 2 development of its phosphate binder (PT20) for the treatment of a late-stage renal disease suffer from systemic phosphate accumulation, hyperphosphataemia, whose global rights were acquired from the Medical Research Council.
The PT20 programme was initially supported by funding from the MRC’s Development Gap Fund.
The company is led by CEO Carl Sterritt.
FinSMEs
05/03/2012